An Introduction to Semaglutide
Semaglutide was first approved by the FDA in 2017 as a once-weekly injection for improving glycemic control in adults with type 2 diabetes. It belongs to a class of medications known as GLP-1 receptor agonists that work by mimicking the effects of a hormone called glucagon-like peptide-1. This hormone helps regulate blood sugar levels by stimulating the release of insulin when blood sugar is high, suppressing glucagon secretion, slowing digestion, and increasing feelings of fullness.
Beyond diabetes, semaglutide was approved for chronic weight management in 2021 based on strong clinical trial results showing significant weight loss and improvements in cardiovascular risk factors. This makes semaglutide the first GLP-1 receptor agonist to be approved for obesity treatment.